retatrutide type 2 diabetes phase 2 results 2024 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 🚀 READY TO LEVEL UP

Both drugs may cause mild but manageable GI side effects , such as nausea, vomiting, and diarrhea

The Retadose app computes this using published PK parameters (Coskun et al

Conclusions The excessive activation of neural circuitry involving afferent and efferent renal nerves suppresses diuretic and natriuretic responses to GLP-1 in HF

They're everywhere

Males ages 19-50 need at least 38 grams of fiber daily, while those 51 and older need at least 30 grams

GLP-1 receptor agonistsmedications like semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), and dulaglutide (Trulicity)are widely prescribed for type 2 diabetes and weight management